Sarepta Therapeutics Inc Q2 2023 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Congrats on another mark then with the first patient dosed. I guess a sort of 2-part question around the comments you made around EMBARK. Hitting with as low as a 1.3 point delta. I'm curious, what is the powering the 1.3 delta is at? And has there been any discussion with FDA whether this would be considered clinically meaningful? And then just as a sort of follow-up on that, I think the most common question we're getting is that if EMBARK misses the primary and the overall population that shows a directional benefit in 4- to 5-year-olds, given there's no multiplicity strategy, has the FDA given any indication on whether this would be sufficient to maintain the approval status? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 02, 2023 / 8:30PM, SRPT.OQ - Q2 2023 Sarepta Therapeutics Inc Earnings Call

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Congrats on today's milestone. Given that you're taking all these steps now across sites, payers and antibody testing, is it your expectation that if you end up getting a broader label in the first half of next year, that the 3- to 4-month timeline you've commuted -- you've communicated to us in terms of patients getting on therapy could be shortened?